🎉 Up to 70% Off Selected ItemsShop Sale
HomeStore

Mavyret 100mg 40mg Tab

Product image 1
Product image 2
Product image 3

Mavyret 100mg 40mg Tab

Mavyret Glecaprevir/Pibrentasvir 100mg/40mg Tablets

Mavyret is a fixed-dose combination medication containing glecaprevir and pibrentasvir, designed for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older. This medication is effective against multiple HCV genotypes (1, 2, 3, 4, 5, or 6) and is suitable for patients with or without compensated cirrhosis.

Key Features
  • Combination of glecaprevir, an HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.
  • Indicated for patients previously treated with an NS5A inhibitor or an NS3/4A protease inhibitor.
  • Suitable for pediatric patients 3 years and older.
Technical Specifications
  • Active Ingredients Glecaprevir 100mg, Pibrentasvir 40mg
  • Dosage Form Tablet
  • Administration Oral, with food
Application or Use Case

Primarily used for treating chronic hepatitis C in various genotypes.

Typical User/Industry Profile

Healthcare providers, patients with chronic HCV infection.

About the Brand

AbbVie Inc, the manufacturer of Mavyret, is a leader in the pharmaceutical industry, known for its innovative treatments for chronic diseases, including hepatitis C.

$5,538.49

Original: $15,824.25

-65%
Mavyret 100mg 40mg Tab—

$15,824.25

$5,538.49

Product Information

Shipping & Returns

Description

Mavyret Glecaprevir/Pibrentasvir 100mg/40mg Tablets

Mavyret is a fixed-dose combination medication containing glecaprevir and pibrentasvir, designed for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older. This medication is effective against multiple HCV genotypes (1, 2, 3, 4, 5, or 6) and is suitable for patients with or without compensated cirrhosis.

Key Features
  • Combination of glecaprevir, an HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.
  • Indicated for patients previously treated with an NS5A inhibitor or an NS3/4A protease inhibitor.
  • Suitable for pediatric patients 3 years and older.
Technical Specifications
  • Active Ingredients Glecaprevir 100mg, Pibrentasvir 40mg
  • Dosage Form Tablet
  • Administration Oral, with food
Application or Use Case

Primarily used for treating chronic hepatitis C in various genotypes.

Typical User/Industry Profile

Healthcare providers, patients with chronic HCV infection.

About the Brand

AbbVie Inc, the manufacturer of Mavyret, is a leader in the pharmaceutical industry, known for its innovative treatments for chronic diseases, including hepatitis C.